Last reviewed · How we verify
Standard dose gabapentin
Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby decreasing calcium influx and neurotransmitter release.
Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby decreasing calcium influx and neurotransmitter release. Used for Postherpetic neuralgia (neuropathic pain following herpes zoster), Partial-onset seizures (adjunctive therapy), Neuropathic pain conditions.
At a glance
| Generic name | Standard dose gabapentin |
|---|---|
| Also known as | Standard gabapentin |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant; gabapentinoid |
| Target | Alpha-2-delta-1 subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Gabapentin is a structural analogue of gamma-aminobutyric acid (GABA) that crosses the blood-brain barrier and binds to the alpha-2-delta-1 subunit of presynaptic voltage-gated calcium channels. This binding reduces calcium entry into nerve terminals, which decreases the release of excitatory neurotransmitters including glutamate, noradrenaline, and substance P. The net effect is reduced neuronal firing and pain signal transmission.
Approved indications
- Postherpetic neuralgia (neuropathic pain following herpes zoster)
- Partial-onset seizures (adjunctive therapy)
- Neuropathic pain conditions
- Off-label: generalized anxiety disorder, restless leg syndrome
Common side effects
- Dizziness
- Somnolence
- Ataxia
- Fatigue
- Peripheral edema
- Tremor
- Headache
Key clinical trials
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
- Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy(LSG) (PHASE4)
- The Effect of Preoperative Gabapentin on Postoperative Pain Control and Analgesic Requirements Following Bariatric Surgery (NA)
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery (PHASE3)
- Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries (PHASE4)
- Assessment of Safety and Efficacy of Gabapentin After Surface Ablation, a Case Control Experimental Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose gabapentin CI brief — competitive landscape report
- Standard dose gabapentin updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI